Edition:
United States

Quidel Corp (QDEL.OQ)

QDEL.OQ on NASDAQ Stock Exchange Global Select Market

43.10USD
25 Sep 2017
Change (% chg)

-- (--)
Prev Close
$43.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
112,344
52-wk High
$45.49
52-wk Low
$18.25

Latest Key Developments (Source: Significant Developments)

Quidel Q2 GAAP loss per share $0.35
Wednesday, 26 Jul 2017 04:10pm EDT 

July 26 (Reuters) - Quidel Corp ::Quidel reports second quarter 2017 financial results.Q2 GAAP loss per share $0.35.Q2 revenue $38.3 million versus I/B/E/S view $41.8 million.Q2 non-GAAP loss per share $0.12.Q2 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.  Full Article

Quidel announces definitive agreement to acquire Alere Triage assets
Monday, 17 Jul 2017 06:00am EDT 

July 17 (Reuters) - Quidel Corp :Quidel Corp - ‍accretive transactions extend Quidel's market leadership and position it for future growth​.Quidel Corp- ‍transactions will be funded through a combination of cash on hand and committed financing​.Quidel Corp - to buy Triage business and B-type Naturietic Peptide (BNP) business for a total consideration of $400 million plus $40 million in contingent consideration​.Quidel Corp - ‍transactions are to be financed with cash plus committed financing from Bank of America Merrill Lynch and J.P. Morgan Chase Bank.Quidel Corp - ‍Quidel will distribute Triage MeterPro products and BNP assays through a combination of direct sales force and distributors​.  Full Article

Quidel receives the CE mark for its thyretain tbi reporter bioassay
Wednesday, 7 Jun 2017 06:00pm EDT 

June 7 (Reuters) - Quidel Corp ::Quidel receives the CE mark for its thyretain® tbi reporter bioassay.  Full Article

Quidel gets FDA clearance, CLIA waiver for Sofia 2 Immunoassay analyzer
Tuesday, 30 May 2017 02:15pm EDT 

May 30 (Reuters) - Quidel Corp ::Quidel receives FDA clearance and CLIA waiver for its point-of-care Sofia 2 Immunoassay analyzer for use with Sofia Influenza A+B Assay.  Full Article

Quidel receives PMDA approval for its point-of-care SOFIA Influenza A+B Assay
Wednesday, 24 May 2017 06:30pm EDT 

May 24 (Reuters) - Quidel Corp :Quidel receives PMDA approval for its point-of-care Sofia Influenza A+B Assay.Approval from Japan's PMDA for Sofia Influenza A+B fluorescent immunoassay to be used with Sofia Fluorescent Immunoassay Analyzer.  Full Article

Quidel receives FDA clearance for Solana(R) molecular assay for detecting C. difficile infections
Thursday, 11 May 2017 02:30pm EDT 

May 11 (Reuters) - Quidel Corp ::Quidel receives FDA clearance for its new Solana(R) molecular assay for the detection of Clostridium difficile (C. difficile) infections.Received 510(k) clearance from U.S. FDA to market its Solana C. difficile Assay for detection of Clostridium difficile (C. difficile) infections.  Full Article

Quidel reports Q1 earnings per share $0.42
Monday, 24 Apr 2017 04:10pm EDT 

April 24 (Reuters) - Quidel Corp -:Quidel reports first quarter 2017 financial results.Q1 gaap earnings per share $0.42.Q1 revenue $73.7 million versus i/b/e/s view $60.8 million.Q1 earnings per share view $0.14 -- Thomson Reuters I/B/E/S.Q1 non-gaap earnings per share $0.45.  Full Article

Quidel reports Q4 gaap loss per share $0.06
Wednesday, 8 Feb 2017 04:10pm EST 

Quidel Corp : Quidel reports fourth quarter and full year 2016 financial results . Q4 GAAP loss per share $0.06 . Q4 revenue $52.8 million versus I/B/E/S view $57.5 million . Q4 earnings per share view $0.10 -- Thomson Reuters I/B/E/S .Q4 non-GAAP earnings per share $0.17.  Full Article

Quidel Corp says voluntarily terminated its $140.0 million senior secured syndicated credit facility
Friday, 2 Dec 2016 04:17pm EST 

Quidel Corp : Quidel corp - on december 1 voluntarily terminated its $140.0 million senior secured syndicated credit facility . Quidel corp - in connection with termination, company expects to incur a charge in q4 of $0.2 million .Quidel corp - from termination date to maturity date in august 2017 company anticipates cost savings of approximately $0.6 million..  Full Article

Quidel reports Q3 GAAP loss per share $0.02
Wednesday, 26 Oct 2016 04:10pm EDT 

Quidel Corp : Quidel reports third quarter 2016 financial results . Q3 non-gaap earnings per share $0.10 . Q3 gaap loss per share $0.02 . Q3 revenue $49.3 million versus i/b/e/s view $50.9 million .Q3 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Quidel announces revised agreement for pending acquisition of Alere’s business

* Quidel announces revised agreement for its pending acquisition of Alere’s B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter Analyzers